Document Detail

Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study.
MedLine Citation:
PMID:  16213136     Owner:  NLM     Status:  MEDLINE    
The objective of this prospective, randomised study was to compare the efficacy, safety and tolerability of vaginal micronised progesterone with oral dydrogesterone as luteal phase support after in-vitro fertilisation (IVF). A total of 430 women underwent IVF/intracytoplasmic sperm injection (ICSI) treatment. Long protocol gonadotropin releasing hormone analogue down-regulation was followed by gonadotropin stimulation. Human chorionic gonadotropin was given when two or more follicles reached > or = 17 mm. After 36 h, oocytes were retrieved and IVF was performed. Embryo transfer was done at the 4-8 cell embryo stage. Luteal support was initiated from the day of embryo transfer and continued for up to 14 days. Patients were randomised to luteal supplementation with either intravaginal micronised progesterone 200 mg three times daily (n=351) or oral dydrogesterone 10 mg twice daily (n=79). In cases of a positive pregnancy test, luteal support was continued for 12 weeks. Both dydrogesterone and micronised progesterone were associated with similar rates of successful pregnancies. Vaginal discharge or irritation were reported by 10.5% of patients given micronised progesterone. Significantly (p<0.05), more patients given dydrogesterone than micronised progesterone were satisfied with the tolerability of their treatment. There were no differences between the treatments with regard to liver function tests.
Baidya Nath Chakravarty; Hasibul Hasan Shirazee; Purvita Dam; Sourendra Kanta Goswami; Ratna Chatterjee; Sanghamitra Ghosh
Related Documents :
21377276 - Do neurotrophins regulate the feto-placental development?
21481146 - Transvaginal removal of ectopic pregnancy tissue and repair of uterine defect for caesa...
21335936 - Prevalence and outcome of absence of ductus venosus at 11 to 13(+6) weeks.
21495456 - The three-dimensional ultrasonography of the fetal face--history and progresses.
19377426 - Risk factors for the development of gestational diabetes mellitus.
10770096 - The accuracy of antenatal fetal echocardiography.
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial     Date:  2005-10-05
Journal Detail:
Title:  The Journal of steroid biochemistry and molecular biology     Volume:  97     ISSN:  0960-0760     ISO Abbreviation:  J. Steroid Biochem. Mol. Biol.     Publication Date:  2005 Dec 
Date Detail:
Created Date:  2005-12-02     Completed Date:  2006-02-03     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9015483     Medline TA:  J Steroid Biochem Mol Biol     Country:  England    
Other Details:
Languages:  eng     Pagination:  416-20     Citation Subset:  IM    
Department of ART, Institute of Reproductive Medicine, Calcutta 700106, West Bengal, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Intravaginal
Administration, Oral
Chorionic Gonadotropin / administration & dosage,  metabolism,  pharmacology
Dydrogesterone / administration & dosage*,  metabolism,  pharmacology
Embryo Transfer
Fertilization in Vitro
Luteal Phase / drug effects*
Pregnancy Outcome
Pregnancy Rate
Progesterone / administration & dosage*,  pharmacology
Prospective Studies
Reproductive Techniques, Assisted*
Sperm Injections, Intracytoplasmic / drug effects
Reg. No./Substance:
0/Chorionic Gonadotropin; 152-62-5/Dydrogesterone; 57-83-0/Progesterone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Transcription inhibition: a potential strategy for cancer therapeutics.
Next Document:  Effects of storage conditions of Moringa oleifera seeds on its performance in coagulation.